Drugs / OMS103HP
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00624845 | Dec 2007 → May 2009 | — | Omeros Corporation | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT01406561 | Aug 2011 → Nov 2012 | — | Omeros Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00226772 | Jun 2005 → Sep 2010 | — | Omeros Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00226759 | Nov 2004 → Sep 2010 | — | Omeros Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00245271 | Oct 2004 → Mar 2010 | — | Omeros Corporation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMS103HP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00226759 ↗ |
| Known as | OMS103HP-S | “Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery” NCT01406561 ↗ |
| Action | Inhibit | “to inhibit inflammation and pain before they can begin” NCT00226772 ↗ |
| Modality | Other / unclassified | “OMS103 provides a multicomponent approach to controlling the inflammation induced by arthroscopic surgery.” NCT00245271 ↗ |
| Route | Other | “directly to the surgical site during the arthroscopic procedure” NCT00226772 ↗ |